Clinical Trials Browser

INDUSTRY × Neoplasms × trametinib × Clear all

NCT05275374 2025-04-10

ENHANCE

Phase 1/2 Not yet recruiting

DermatologicGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms

NCT01682083 2023-08-30

COMBI-AD

Phase 3 Completed

870 enrolled 13 charts 1 FDA

Melanoma, Neoplasms

NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Phase 2 Completed

206 enrolled 40 charts 2 FDA

CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

NCT01336634 2022-04-04

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

Phase 2 Completed

177 enrolled 19 charts 1 FDA

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Phase 1 Completed

BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

NCT02083354 2022-02-01

Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

Phase 2 Completed

77 enrolled 43 charts

Melanoma, Neoplasms, Skin Neoplasms

NCT02110355 2021-03-26

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

Phase 1 Completed

Melanoma, Neoplasms

NCT01938443 2019-07-12

A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasmThoracic

Mesothelioma, Neoplasms

NCT01072175 2019-07-05

Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

Phase 2 Completed

430 enrolled 61 charts

Melanoma, Neoplasms

NCT01231594 2019-03-22

A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

Phase 1 Completed

Neoplasms

NCT01376310 2019-02-19

GSK1120212 Rollover Study

Phase 2 Terminated

159 enrolled 9 charts

Neoplasms

NCT02314143 2019-02-18

Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib

Phase 2 Terminated

48 enrolled 20 charts

Melanoma, Neoplasms

NCT02939846 2018-09-14

Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours

Phase 1 Withdrawn

Neoplasms

NCT02065063 2018-06-01

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors

Phase 1 Completed

Melanoma, Neoplasms

NCT01245062 2018-04-05

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

Phase 3 Completed

322 enrolled 24 charts

Melanoma, Neoplasms

NCT01328106 2017-12-12

Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma

Phase 2 Withdrawn

Uveal Melanoma, Neoplasms

NCT00687622 2017-11-13

Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma

Phase 1 Completed

Melanoma, Neoplasms

NCT01138085 2017-11-13

Safety, Pharmacokinetics (PK) of AKT and MEK Combination

Phase 1 Completed

BreastGynecologic

Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT01192165 2017-11-13

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Phase 1 Completed

Neoplasms

NCT01371487 2017-11-13

GSK1120212 Food-effect Study

Phase 1 Completed

Neoplasms

NCT01387204 2017-11-13

Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212

Phase 1 Completed

Neoplasms

NCT01416337 2017-11-13

Absolute Bioavialability of GSK1120212

Phase 1 Completed

Neoplasms

NCT00955773 2017-11-09

Cancer

Phase 1 Completed

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT02538627 2017-09-05

Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib

Phase 1 Terminated

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Neoplasms, Colorectal Neoplasms

NCT01943864 2017-05-31

A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers

Phase 2 Completed

20 enrolled 27 charts

Gastrointestinal

Biliary Tract Neoplasms, Neoplasms

NCT01248858 2017-05-09

Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.

Phase 1 Terminated

Neoplasms

NCT02292732 2016-01-26

A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors

Phase 1 Withdrawn

Neoplasms